Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease?
| Autor: | Deyà-Martinez A, Gordón Y, Molina-Anguita C, Vlagea A, Piquer-Gibert M, Manel Juan Otero, Esteve-Sole A, Anton-Lopez J, Madrid Á, García-García A, Plaza-Martín AM, Armangue-Salvador T, Alsina L |
|---|---|
| Rok vydání: | 2020 |
| Zdroj: | NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu Fundació Sant Joan de Déu r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu instname |
| ISSN: | 2332-7812 |
| Popis: | OBJECTIVE: To investigate the immunologic impact of a single cycle of rituximab (RTX) in children and adolescents with immune-mediated disorders, we evaluated B cells and immunoglobulin levels of 20 patients with neuroimmunologic, nephrologic, dermatologic, and rheumatologic disorders treated under recommended guidelines. METHODS: Retrospective study of immunologic changes in children (aged =18 years) diagnosed with immune-mediated disorders in which RTX was prescribed between June 2014 and February 2019. Patients were excluded if they had prior diagnosis of malignant disease or primary immunodeficiency. Patients were clinically and immunologically followed up every 3 months. Only patients having received a single cycle of RTX and with a follow-up greater than 12 months were included in the analysis of persistent dysgammaglobulinemia. RESULTS: Twenty children were included. Median age at RTX treatment was 12.8 years (interquartile range [IQR] 6.6-15.5 years). Median follow-up was 12.6 months (IQR 10.2-24 months). Of the 14 patients eligible for persistent dysgammaglobulinemia analysis (3 had received RTX retreatment, 2 had |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|